Salmeterol

also known as salmeterol xinafoate · SAL · Serevent · Serevent Diskus · Salm · 408DP-02 · SAL 50 · Salm25PE · +4 more

Developed for: asthma · chronic obstructive pulmonary disease · exercise-induced bronchoconstriction · allergic asthma · chronic bronchitis · pulmonary emphysema · bronchiectasis · cystic fibrosis
+7 more
· environmental induced asthma · high altitude pulmonary edema · lipodystrophy · lung disorder · transplant-related bronchiolitis obliterans · allergic rhinitis · spinal cord injury
Investigated by: GlaxoSmithKline · Boehringer Ingelheim · Novartis Pharmaceuticals · AstraZeneca · National Heart, Lung, and Blood Institute (NHLBI) · Novartis
+65 more
· Teva Branded Pharmaceutical Products R&D, Inc. · University of Copenhagen · Milton S. Hershey Medical Center · Organon and Co · Orion Corporation, Orion Pharma · Parexel · Taipei Veterans General Hospital, Taiwan · University of British Columbia · University of Milan · Università degli Studi di Ferrara · Academisch Ziekenhuis Groningen · Actavis Inc. · Allergy and Asthma Center of El Paso · Assistance Publique - Hôpitaux de Paris · Assiut University · Asthma Clinical Research Network · Bispebjerg Hospital · Brian J Lipworth · Brighton and Sussex University Hospitals NHS Trust · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chiesi Farmaceutici S.p.A. · Childhood Asthma Research and Education Network · Cipla Ltd. · Elpen Pharmaceutical Co. Inc. · European Research Council · FLUIDDA nv · Far Eastern Memorial Hospital · Fondazione Salvatore Maugeri · Fraunhofer-Institute of Toxicology and Experimental Medicine · Hanmi Pharmaceutical Company Limited · Hormone Laboratory, Aker University Hospital, Oslo, Norway · Imperial College London · Inje University · JHSPH Center for Clinical Trials · Kindeva Drug Delivery · Leiden University Medical Center · McGill University Health Centre/Research Institute of the McGill University Health Centre · Merck Sharp & Dohme LLC · National Center for Research Resources (NCRR) · National Jewish Health · National Taiwan University Hospital · Nemours Children's Clinic · Neothetics, Inc · Netherlands Organisation for Scientific Research · Neutec Ar-Ge San ve Tic A.Ş · Northwestern University · Parc de Salut Mar · Pfizer · Professor Warren Lenney · Queen's University · Respirent Pharmaceuticals Co Ltd. · Seoul National University Hospital · Shanghai Pulmonary Hospital, Shanghai, China · Shin-hwar Wu · Sumitomo Pharma America, Inc. · The Netherlands Asthma Foundation · United States Department of Defense · University of California, Los Angeles · University of Colorado, Denver · University of Dundee · University of Miami · University of Rostock · University of Southampton · University of Sussex · University of Wisconsin, Madison

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed asthma 1 milestone
Filed	EU (EMA)	—	asthma	—	“In April 2017 Orion submitted a marketing authorisation application for a salmeterol-fluticasone combined formulation in Europe” orionpharma.com ↗
Approved Indication not stated 2 milestones
Approved	EU (EMA)	Aerivio Spiromax	—	2016-08-18	europa.eu ↗
Refused (EMA)	EU (EMA)	Labazenit	—	2013-09-06	europa.eu ↗

Trials 147 · started per year

today

EU approved 2016

20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT05748977	Feb 2023 → Feb 2024	chronic obstructive pulmonary disease	Assiut University	Unknown	No outcome recorded
Phase 115 trials · 1 met primary
Phase 1	NCT04195867	Nov 2018 → Jan 2019	—	Parc de Salut Mar	Completed	No outcome recorded
Phase 1	NCT03238482	Aug → Dec 2017	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT02441114	Jul → Oct 2015	chronic obstructive pulmonary disease	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT02437604	May → Jul 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT02218762	Oct 2014 → Jun 2015	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 1	NCT02232087	Jul → Oct 2014	—	Kindeva Drug Delivery	Completed	Met primary
Phase 1	NCT01890863	Aug → Sep 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01564199	Apr → Jun 2012	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01521455	Feb 2012 → Jun 2013	asthma	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 1	NCT01540708	Jan → Sep 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02254174	Mar → Jul 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02254187	Sep → Oct 2005	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00364273	Aug 2005 → Jul 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00364442	Jan → Apr 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02254226	Nov 2004 → Jan 2005	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT06040268	Dec 2023 → Dec 2026 expected	high altitude pulmonary edema	University of Colorado, Denver	Recruiting	No outcome recorded
Phase 1/2	NCT01494610	Oct 2010 → Jun 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 215 trials · 5 met primary
Phase 2	NCT02833480	Feb 2015 → Jan 2021	chronic obstructive pulmonary disease	University of British Columbia	Unknown	No outcome recorded
Phase 2	NCT01802723	Feb → Jun 2013	lipodystrophy	Neothetics, Inc	Completed	No outcome recorded
Phase 2	NCT01048333	Jan → May 2010	chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 2	NCT00557440	Nov 2007 → Apr 2008	asthma	Novartis	Completed	Met primary
Phase 2	NCT00556673	Oct 2007 → Apr 2008	asthma	Novartis	Completed	Met primary
Phase 2	NCT00531050	Aug 2007 → Jun 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 2	NCT00468975	May 2007 → ?	asthma	Pfizer	Completed	No outcome recorded
Phase 2	NCT00403754	Nov 2006 → Nov 2007	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00422604	Oct 2006 → May 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00350207	Jul 2006 → Sep 2008	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT00358488	Apr 2006 → Jan 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00325169	Dec 2005 → Aug 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT02238106	Sep 2005 → Feb 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242227	Sep 2005 → Feb 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242253	Sep 2003 → Jul 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 339 trials · 7 met primary · 2 missed
Phase 3	NCT05776927	Aug 2026 → Dec 2028 expected	asthma	Novartis Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT04655508	May 2021 → Sep 2023	disease related to hematopoietic stem cell transplant, transplant-related bronchiolitis obliterans	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT03394989	Oct 2018 → Dec 2019	asthma	Cipla Ltd.	Completed	No outcome recorded
Phase 3	NCT03676413	Oct 2018 → Aug 2019	asthma	Respirent Pharmaceuticals Co Ltd.	Completed	No outcome recorded
Phase 3	NCT03461627	Apr 2017 → Oct 2018	asthma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT02980133	Dec 2016 → Apr 2019	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Mixed
Phase 3	NCT02496715	Sep 2015 → Oct 2016	asthma	Actavis Inc.	Withdrawn	No outcome recorded
Phase 3	NCT02301975	Mar 2015 → Nov 2016	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02175771	Jul 2014 → Jul 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	Met primary
Phase 3	NCT01967173	Feb 2014 → Jul 2017	asthma	Milton S. Hershey Medical Center	Completed	Mixed
Phase 3	NCT01978145	Nov 2013 → Apr 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01978119	Nov 2013 → Jan 2015	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01795664	Mar → Aug 2013	asthma	FLUIDDA nv	Completed	No outcome recorded
Phase 3	NCT01079130	Feb → Jul 2010	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00673478	May 2008 → Jun 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00668772	Apr → Nov 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 3	NCT00662792	Apr 2008 → Jul 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Mixed
Phase 3	NCT01484210	Mar → Aug 2008	asthma	Elpen Pharmaceutical Co. Inc.	Completed	No outcome recorded
Phase 3	NCT00622635	Jan → Jul 2008	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00615030	Jan → Jul 2008	chronic obstructive pulmonary disease	Novartis	Completed	Met primary
Phase 3	NCT00529529	Sep 2007 → Aug 2008	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00449046	Mar → Nov 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00395304	Mar 2007 → Dec 2011	asthma	Milton S. Hershey Medical Center	Completed	Met primary
Phase 3	NCT00441441	Feb 2007 → Jan 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00411372	Nov 2006 → ?	chronic obstructive pulmonary disease	GlaxoSmithKline	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT00245570	Dec 2005 → Sep 2006	exercise-induced bronchoconstriction	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00127166	Dec 2005 → Nov 2008	exercise-induced bronchoconstriction	Organon and Co	Completed	Met primary
Phase 3	NCT00328718	Oct 2005 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00242775	May 2005 → May 2006	asthma	AstraZeneca	Completed	Missed primary
Phase 3	NCT00269126	Feb → Aug 2005	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00252863	Dec 2004 → May 2006	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00200967	Dec 2004 → Feb 2008	asthma	Milton S. Hershey Medical Center	Completed	Missed primary
Phase 3	NCT00549146	Nov 2003 → Apr 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00268177	Oct 2002 → Dec 2003	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00272506	Aug 2002 → Sep 2004	asthma, lung disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT00274560	May 2002 → Mar 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00920959	Nov 2001 → Jan 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00274534	Dec 2000 → Jul 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00268216	Sep 2000 → Nov 2005	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded

Phase 461 trials · 12 met primary · 8 missed
Phase 4	NCT04503460	Jul 2021 → Sep 2024	asthma	Imperial College London	Unknown	No outcome recorded
Phase 4	NCT04677959	Feb 2021 → Mar 2022	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT03662711	Nov 2018 → Oct 2022	chronic obstructive pulmonary disease	Università degli Studi di Ferrara	Terminated	No outcome recorded
Phase 4	NCT03363503	Apr 2018 → Apr 2022	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Terminated	No outcome recorded
Phase 4	NCT03269318	Jul 2017 → Aug 2019	asthma	Brighton and Sussex University Hospitals NHS Trust	Terminated	No outcome recorded
Phase 4	NCT03034915	Jun 2017 → Jun 2018	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT02558088	Sep 2014 → Jul 2016	—	University of Copenhagen	Completed	No outcome recorded
Phase 4	NCT02546349	Jul 2014 → Dec 2015	chronic obstructive pulmonary disease	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
Phase 4	NCT01853787	Jul 2014 → Jun 2015	chronic obstructive pulmonary disease	University of Milan	Completed	No outcome recorded
Phase 4	NCT02055352	May 2014 → Jan 2016	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	Met primary
Phase 4	NCT02113436	May 2014 → Jun 2016	asthma	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT02061280	Oct 2013 → Feb 2017	asthma	Nemours Children's Clinic	Completed	Mixed
Phase 4	NCT01794780	Feb 2013 → May 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01762800	Feb 2013 → Sep 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01536587	Jul → Nov 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT01607398	May 2012 → Jul 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT01475721	Nov 2011 → Jun 2015	asthma	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT01462344	Nov 2011 → Nov 2015	asthma	GlaxoSmithKline	Completed	Mixed
Phase 4	NCT01361984	Jun 2011 → Jun 2013	chronic bronchitis, pulmonary emphysema	University of California, Los Angeles	Unknown	No outcome recorded
Phase 4	NCT02782312	Jun 2011 → Jun 2012	bronchiectasis	Shanghai Pulmonary Hospital, Shanghai, China	Completed	No outcome recorded
Phase 4	NCT01192178	Aug → Dec 2010	asthma	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT01124422	Jul 2010 → May 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT00974805	Feb 2010 → Feb 2012	chronic obstructive pulmonary disease	University of Southampton	Completed	No outcome recorded
Phase 4	NCT01131806	Dec 2009 → Nov 2010	chronic obstructive pulmonary disease	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
Phase 4	NCT01194700	Nov → Dec 2009	asthma	Brian J Lipworth	Completed	No outcome recorded
Phase 4	NCT00984659	Oct 2009 → Jul 2010	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Mixed
Phase 4	NCT00914901	Jul 2009 → Mar 2011	asthma	Bispebjerg Hospital	Unknown	No outcome recorded
Phase 4	NCT00901368	May 2009 → Sep 2010	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 4	NCT00830505	Apr 2009 → May 2010	asthma	University of Dundee	Completed	Met primary
Phase 4	NCT01526161	Apr 2009 → Jun 2010	asthma	Professor Warren Lenney	Completed	No outcome recorded
Phase 4	NCT00784550	Dec 2008 → Dec 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00867737	Sep 2008 → Sep 2009	asthma	Allergy and Asthma Center of El Paso	Unknown	No outcome recorded
Phase 4	NCT02136875	Jul 2008 → Aug 2010	chronic obstructive pulmonary disease	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 4	NCT00633217	Mar 2008 → Feb 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00530842	Sep 2007 → Jan 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Mixed
Phase 4	NCT00517634	Aug 2007 → Jul 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00712335	Feb 2007 → May 2011	environmental induced asthma	Inje University	Completed	No outcome recorded
Phase 4	NCT00346749	Dec 2006 → Jul 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Terminated	No outcome recorded
Phase 4	NCT00400608	Oct 2006 → Feb 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00379028	Sep 2006 → Jul 2007	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00363480	May 2006 → Sep 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00358358	Mar 2006 → Feb 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00353873	Nov 2005 → Oct 2006	asthma	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00291382	Nov 2005 → Jul 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00120978	Dec 2004 → Aug 2006	chronic obstructive pulmonary disease	University of British Columbia	Unknown	Missed primary
Phase 4	NCT00115492	Dec 2004 → Jun 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00315744	Nov 2004 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00102765	Nov 2004 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00102882	Oct 2004 → Jan 2007	asthma	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT00144911	Oct 2004 → Dec 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00355342	Apr 2004 → Sep 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00327353	Jan 2004 → ?	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00118716	Dec 2003 → Apr 2006	exercise-induced bronchoconstriction	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00118690	Dec 2003 → Dec 2005	exercise-induced bronchoconstriction	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00239421	Nov 2003 → Sep 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT00239499	Sep 2003 → Aug 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00950794	Sep 2003 → Feb 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00156819	Jun 2003 → Aug 2005	asthma	JHSPH Center for Clinical Trials	Completed	Missed primary
Phase 4	NCT00361959	Jun 2003 → Feb 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00479739	Nov 2002 → Jul 2004	asthma	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00158847	Apr 2000 → May 2005	chronic obstructive pulmonary disease	Leiden University Medical Center	Terminated	Met primary

Phase not applicable14 trials · 2 met primary
—	NCT06654986	Oct 2024 → Dec 2026 expected	—	University of Copenhagen	Recruiting	No outcome recorded
—	NCT06657547	Oct 2024 → Dec 2026 expected	—	University of Copenhagen	Recruiting	No outcome recorded
—	NCT06655012	Oct 2024 → Dec 2026 expected	—	University of Copenhagen	Recruiting	No outcome recorded
—	NCT03524066	Apr → Dec 2018	—	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
—	NCT02758873	Feb 2016 → Jul 2019	asthma	University of Sussex	Completed	Met primary
—	NCT01933984	Aug 2013 → Jan 2019	chronic obstructive pulmonary disease	Shin-hwar Wu	Completed	No outcome recorded
—	NCT01271556	Dec 2008 → Mar 2009	chronic obstructive pulmonary disease	University of Milan	Completed	No outcome recorded
—	NCT00741767	Aug 2008 → Sep 2010	chronic obstructive pulmonary disease, sleep disorder	Northwestern University	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00559312	Dec 2007 → Mar 2010	chronic obstructive pulmonary disease	Queen's University	Completed	No outcome recorded
—	NCT01231230	May 2007 → Dec 2009	asthma	University of Miami	Completed	Met primary
—	NCT00736801	Sep 2005 → Jan 2007	allergic asthma	University of Rostock	Completed	No outcome recorded
—	NCT00214019	Nov 2003 → Jan 2008	allergic asthma	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT00233051	Apr 2003 → Jun 2006	chronic bronchitis, pulmonary emphysema	National Jewish Health	Terminated	No outcome recorded
—	NCT00005110	—	cystic fibrosis	National Center for Research Resources (NCRR)	Suspended	No outcome recorded

Comparator or background therapy131 trials
Phase 1	NCT02474017 Background	May → Jun 2015	asthma, chronic obstructive pulmonary disease	Mylan Pharma UK Ltd.	Completed	No outcome recorded
Phase 1	NCT02162485 Comparator	Jun 2014 → Sep 2015	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01355991 Comparator	Aug 2011 → Mar 2016	spinal cord injury	James J. Peters Veterans Affairs Medical Center	Unknown	No outcome recorded
Phase 1	NCT00908362 Comparator	May → Oct 2009	chronic obstructive pulmonary disease	University of Rostock	Completed	No outcome recorded
Phase 1	NCT02256722 Comparator	Oct → Nov 2005	—	Boehringer Ingelheim	Completed	No outcome recorded
Show all 131 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 37

Date	Issuer	Release
2021-09-03	Novartis Pharmaceuticals	Results Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions novartis.com ↗
2020-06-05	Novartis Pharmaceuticals	Results Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma novartis.com ↗ Once-daily Enerzair ® Breezhaler ® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving quality of life in people with uncontrolled asthma 1 .
2019-07-15	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder tevapharm.com ↗
2018-03-19	Orion Corporation, Orion Pharma	Regulatory Orion has received positive conclusions for the salmeterol-fluticasone Easyhaler® combination under the EU's decentralized procedures orionpharma.com ↗ Orion Corporation has received positive conclusions for the salmeterol-fluticasone Easyhaler® combination under the EU's decentralized procedures (DCP).
2017-12-21	GlaxoSmithKline	Regulatory FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data gsk.com ↗ These labelling updates were approved on December 20th 2017, after a review of safety data from 4 randomized controlled safety trials submitted by three companies, including GSK.
2017-11-27	Novartis Pharmaceuticals	Results Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide® novartis.com ↗ Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide ® (salmeterol/fluticasone) 50/500 mcg to Ultibro ® Breezhaler ® (indacaterol/glycopyrronium) 110/50 mcg[1].
2017-06-15	Novartis Pharmaceuticals	Regulatory FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus® novartis.com ↗ Sandoz today announced that the US Food and Drug Administration (FDA) has accepted its Abbreviated New Drug Application for fluticasone propionate / salmeterol combination product, a substitutable generic version of Advair Diskus ® [1].
2017-04-26	Orion Corporation, Orion Pharma	Regulatory Orion Group Interim Report January-March 2017 orionpharma.com ↗ After the review period, in April we submitted a marketing authorisation application for the new salmeterol-fluticasone combined formulation in the Easyhaler product family in Europe.
2017-02-23	GlaxoSmithKline	Results Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma gsk.com ↗ In this positive study we have demonstrated non-inferiority for once-daily Relvar versus twice-daily Seretide on lung function.
2017-01-30	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma tevapharm.com ↗
2016-12-21	Orion Corporation, Orion Pharma	Results Orion is planning to apply for a marketing authorisation for combined salmeterol-fluticasone formulation of the Easyhaler® product family orionpharma.com ↗ Orion Corporation, a Finnish pharmaceutical and diagnostics company, has received favorable pharmacokinetic study results with combined salmeterol-fluticasone formulation of the Easyhaler® product family.
2016-09-05	Boehringer Ingelheim	Results Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment prnewswire.com ↗ It suggests that only 4 in 100 people of the study population – with a history of frequent exacerbations and raised eosinophil levels (≥400 cells/µL) – may benefit by adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) and a long-acting beta 2 -agonist (salmeterol) to further reduce the risk of exacerbations.
2016-09-03	Novartis Pharmaceuticals	Results Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups novartis.com ↗ New analyses from the head-to-head FLAME study confirmed that Ultibro ® Breezhaler ® is a more effective option for patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups (exacerbations) than Seretide ® , across different patient sub-groups[1-10].
2016-09-01	GlaxoSmithKline	Results NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma gsk.com ↗ In the study a non-statistically significant reduction of 14% was observed in the risk of time-to-first asthma exacerbation for FSC compared to FP (HR 0.859; 95% CI 0.729, 1.012).
2016-08-31	Novartis Pharmaceuticals	Results AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment novartis.com ↗ New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
2016-06-28	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick® Inhalers tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug applications (NDAs) for two products for adolescent and adult patients with asthma.
2016-05-16	Nxera Pharma UK Limited	Results Other nxera.life ↗
2016-05-16	Nxera Pharma UK Limited	Results Major study published in NEJM confirms Ultibro Breezhaler superiority over Seretide in preventing COPD exacerbations nxera.life ↗ In addition to meeting the primary endpoint (non-inferiority), findings demonstrated the superiority of Ultibro Breezhaler over the widely used inhaled corticosteroid (ICS)/LABA* combination on exacerbation outcomes 1.
2016-05-15	Novartis Pharmaceuticals	Results Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations novartis.com ↗ In addition to meeting the primary endpoint (non-inferiority), findings demonstrated the superiority of Ultibro Breezhaler over the widely used inhaled corticosteroid (ICS)/LABA* combination on exacerbation outcomes[1].
2016-04-08	Boehringer Ingelheim	Results Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy prnewswire.com ↗ For 80 percent of patients in the WISDOM study, the use of ICS on top of SPIRIVA® HANDIHALER® ‡ and a LABA** had no additional benefit in reducing the risk of exacerbations or 'flare-ups,' compared to SPIRIVA® HANDIHALER® ‡ and a LABA without ICS.
2016-03-17	GlaxoSmithKline	Results GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma gsk.com ↗ The primary safety endpoint of the study showed FSC twice-daily (100/50mcg, 250/50mcg) demonstrated non-inferiority compared to corresponding doses of FP twice-daily (100mcg, 250mcg), on the risk of serious asthma-related events, Hazard Ratio (HR) 1.285, (95% CI 0.726, 2.272) p=0.006.
2016-03-06	GlaxoSmithKline	Results NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma gsk.com ↗ This was assessed by the composite endpoint of serious asthma-related events (deaths, intubations or hospitalisations) and showed that Advair had a safety profile comparable to FP, including no asthma-related deaths in either arm.
2016-02-09	Boehringer Ingelheim	Results Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures prnewswire.com ↗ These newly published data show a lung function improvement among COPD patients with STIOLTO RESPIMAT across a range of commonly used measures of lung function.
2015-11-19	Teva Branded Pharmaceutical Products R&D, Inc.	Results Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma tevapharm.com ↗ Top-line data showed that the studies met their primary endpoints.
2015-11-17	Nxera Pharma UK Limited	Results FLAME Study Shows Superiority of Ultibro Breezhaler over Seretide in Reducing COPD Exacerbations nxera.life ↗
2015-10-27	GlaxoSmithKline	Results GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma gsk.com ↗ There were a total of 67 patients with serious asthma-related events across the study with 34 patients with events on FSC treatment and 33 patients with events on FP treatment.
2015-09-28	Boehringer Ingelheim	Results New Head-to-Head STIOLTO RESPIMAT Data Presented at ERS Annual Congress prnewswire.com ↗ The results from the head-to-head ENERGITO® study build on the growing body of evidence supporting the ability of STIOLTO RESPIMAT to improve lung function in COPD patients.
2014-05-19	GlaxoSmithKline	Results GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD gsk.com ↗
2014-04-30	Nxera Pharma UK Limited	Results Once-daily Ultibro Breezhaler showed superior efficacy versus Seretide for COPD patients in second head-to-head study, and the anticipated timing of China filing nxera.life ↗
2014-03-14	GlaxoSmithKline	Results GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD gsk.com ↗ We are pleased to announce the results from these positive studies, which provide physicians with further data regarding UMEC/VI as a treatment option for appropriate patients with COPD.
2013-09-10	Boehringer Ingelheim	Results Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity prnewswire.com ↗ In the individual trials and the pooled analysis being presented at ERS, the mean change in peak FEV 1 at 24 weeks from baseline versus placebo was significantly improved for all three active treatments:
2013-07-01	Elpen Pharmaceutical Co. Inc.	Regulatory ELPEN PHARMA GmbH: «Δυναμική απόβαση» της ELPEN στη Γερμανία! elpen.gr ↗ H ελληνική φαρμακευτική βιομηχανία ELPEN έγινε η πρώτη φαρμακοβιομηχανία ΠΑΓΚΟΣΜΙΩΣ που έλαβε έγκριση για την κυκλοφορία στην Ευρώπη του συνδυασμού των φαρμακευτικών ουσιών φλουτικαζόνης και σαλμετερόλης (Fluticasone + Salmeterol):
2012-01-09	GlaxoSmithKline	Results GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma gsk.com ↗ There was no statistical difference between FF/VI and FP/SAL.
2011-10-18	Elpen Pharmaceutical Co. Inc.	Regulatory 18.10.2011 Παγκόσμια Αναγνώριση για την ELPEN elpen.gr ↗ Παράλληλα έχει ήδη εγκριθεί με εθνική διαδικασία έγκρισης φαρμάκων σε Ελλάδα, Κύπρο και Μάλτα, όπου κυκλοφορεί.
2010-06-02	AstraZeneca	Regulatory FDA updates US product labels for LABA-containing medications including AstraZeneca’s SYMBICORT astrazeneca.com ↗ Today, the US Food and Drug Administration (FDA) released final label revisions for respiratory medications that contain an active ingredient known as a long-acting beta-agonist (LABA).
2010-06-01	GlaxoSmithKline	Regulatory GSK announces revised product labels for Serevent and Advair gsk.com ↗ GlaxoSmithKline [NYSE:GSK] today announced that it has received a letter from the U.S. Food and Drug Administration directing revisions to product labeling for its respiratory products Serevent® and Advair®.
2010-02-17	GlaxoSmithKline	Regulatory GSK statement on FDA’s proposed label revisions for some asthma medicines gsk.com ↗ GlaxoSmithKline is reviewing label changes proposed today by the US Food and Drug Administration (FDA) for asthma medications containing long-acting beta-agonists (LABAs), such as GSK’s Advair (salmeterol / fluticasone propionate).

All press releases naming this drug 39 releases

Date	Issuer	Release
2021-09-03	Novartis Pharmaceuticals	Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions novartis.com ↗
2020-09-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder tevapharm.com ↗
2020-06-05	Novartis Pharmaceuticals	Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma novartis.com ↗
2019-07-15	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder tevapharm.com ↗
2018-03-19	Orion Corporation, Orion Pharma	Orion has received positive conclusions for the salmeterol-fluticasone Easyhaler® combination under the EU's decentralized procedures orionpharma.com ↗
2017-12-21	GlaxoSmithKline	FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data gsk.com ↗
2017-11-27	Novartis Pharmaceuticals	Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide® novartis.com ↗
2017-06-15	Novartis Pharmaceuticals	FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus® novartis.com ↗
2017-04-26	Orion Corporation, Orion Pharma	Orion Group Interim Report January-March 2017 orionpharma.com ↗
2017-04-20	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol tevapharm.com ↗
2017-02-23	GlaxoSmithKline	Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma gsk.com ↗
2017-01-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma tevapharm.com ↗
2016-12-21	Orion Corporation, Orion Pharma	Orion is planning to apply for a marketing authorisation for combined salmeterol-fluticasone formulation of the Easyhaler® product family orionpharma.com ↗
2016-09-05	Boehringer Ingelheim	Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment prnewswire.com ↗
2016-09-03	Novartis Pharmaceuticals	Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups novartis.com ↗
2016-09-01	GlaxoSmithKline	NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma gsk.com ↗
2016-08-31	Novartis Pharmaceuticals	AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment novartis.com ↗
2016-06-28	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick® Inhalers tevapharm.com ↗
2016-05-16	Nxera Pharma UK Limited	Other nxera.life ↗
2016-05-16	Nxera Pharma UK Limited	Major study published in NEJM confirms Ultibro Breezhaler superiority over Seretide in preventing COPD exacerbations nxera.life ↗
2016-05-15	Novartis Pharmaceuticals	Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations novartis.com ↗
2016-04-08	Boehringer Ingelheim	Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy prnewswire.com ↗
2016-03-17	GlaxoSmithKline	GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma gsk.com ↗
2016-03-06	GlaxoSmithKline	NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma gsk.com ↗
2016-02-09	Boehringer Ingelheim	Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures prnewswire.com ↗
2015-11-19	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma tevapharm.com ↗
2015-11-17	Nxera Pharma UK Limited	FLAME Study Shows Superiority of Ultibro Breezhaler over Seretide in Reducing COPD Exacerbations nxera.life ↗
2015-10-27	GlaxoSmithKline	GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma gsk.com ↗
2015-09-28	Boehringer Ingelheim	New Head-to-Head STIOLTO RESPIMAT Data Presented at ERS Annual Congress prnewswire.com ↗
2014-05-19	GlaxoSmithKline	GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD gsk.com ↗
2014-04-30	Nxera Pharma UK Limited	Once-daily Ultibro Breezhaler showed superior efficacy versus Seretide for COPD patients in second head-to-head study, and the anticipated timing of China filing nxera.life ↗
2014-03-14	GlaxoSmithKline	GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD gsk.com ↗
2013-09-10	Boehringer Ingelheim	Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity prnewswire.com ↗
2013-07-01	Elpen Pharmaceutical Co. Inc.	ELPEN PHARMA GmbH: «Δυναμική απόβαση» της ELPEN στη Γερμανία! elpen.gr ↗
2012-01-09	GlaxoSmithKline	GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma gsk.com ↗
2011-10-18	Elpen Pharmaceutical Co. Inc.	18.10.2011 Παγκόσμια Αναγνώριση για την ELPEN elpen.gr ↗
2010-06-02	AstraZeneca	FDA updates US product labels for LABA-containing medications including AstraZeneca’s SYMBICORT astrazeneca.com ↗
2010-06-01	GlaxoSmithKline	GSK announces revised product labels for Serevent and Advair gsk.com ↗
2010-02-17	GlaxoSmithKline	GSK statement on FDA’s proposed label revisions for some asthma medicines gsk.com ↗

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 284 sources stand behind the page.

Field	Value	Cited text
Known as	Salmeterol	“A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment...” NCT00920543 ↗ 279 “This pilot study was designed to evaluate the pharmacokinetic characteristics of fluticasone, salmeterol, and tiotropium after co-administration of HCP 0910 (Seretide 250...” NCT02441114 ↗ “PURPOSE: Using sputum neutrophils as the primary measure, and other inflammation biomarkers, this study evaluated the anti-inflammatory effects of the combination salmeterol 50...” PMID 25945045 ↗ Apr 2015 “BACKGROUND: This study tested the clinical non-inferiority of the fluticasone propionate/salmeterol combination 50/250 μg (FSC) Rotacaps®/Rotahaler® system, a single unit dose...” PMID 28115223 ↗ Jan 2017 “Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled...” PMID 26006754 ↗ May 2015 “The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug...” NCT01540708 ↗ “Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of...” NCT01110200 ↗ “compare Systemic Exposure and Pharmacodynamics of Fluticasone Propionate and Salmeterol Following Advair HFA 45/21mcg (2 Inhalations), ADVAIR® HFA 45/21mcg (2 Inhalations) With...” NCT00400608 ↗ “Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol...” NCT03376932 ↗ “The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but...” PMID 18245142 ↗ Feb 2008 Show 269 more sources
Known as	408DP-02	“Salmeterol(408DP-02)：long-acting Beta2-agonist” NCT00950794 ↗
Known as	SAL	“The aim of this study was to compare the efficacy of FF/VI with fluticasone propionate (FP)/salmeterol (SAL) in patients with persistent asthma uncontrolled on a medium dose of ICS.” PMID 23846316 ↗ Oct 2013 6 “Subjects were randomized (1:1) to receive fluticasone propionate/salmeterol (FP/SAL) 100/50 mcg or FP 100 mcg prior to starting school.” PMID 26289742 ↗ Jun 2015 “salmeterol/fluticasone propionate (SFC) and salmeterol (SAL) that had primary endpoints of moderate/severe exacerbation rates” PMID 23613569 ↗ Apr 2013 “fluticasone propionate/salmeterol (FP/SAL) (inhaled corticosteroid/LABA)” PMID 26006754 ↗ May 2015 “salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily” PMID 25841237 ↗ Apr 2015 “An active control arm received salmeterol (SAL) twice daily.” PMID 24928338 ↗ Jun 2014 “fluticasone propionate/salmeterol 250/50 µg (FP/SAL)” PMID 28961020 ↗ Apr 2018
Known as	SAL 50	“Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with...” NCT00358358 ↗
Known as	Salm	“The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug...” NCT01540708 ↗ 2 “The participants were then randomized to budesonide/formoterol (Bud + Form; 400/12 μg BID), fluticasone/salmeterol (Flu + Salm; 250/50 μg BID), or formoterol only (12 μg BID)...” PMID 34464242 ↗ Nov 2021 “high-dose salmeterol (SALM)/fluticasone (FP) maintenance plus an as-needed short-acting β(2)-agonist in Chinese patients with persistent uncontrolled asthma” PMID 22932169 ↗ Sep 2012
Known as	Salm25PE	“salmeterol (Salm25PE)” NCT00668772 ↗
Known as	Salm50DPI	“50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)” NCT00662792 ↗
Known as	salmeterol xinafoate	“Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of...” NCT01110200 ↗ 12 “Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses” NCT01393145 ↗ “The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg).” NCT03034915 ↗ “Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.” NCT00355342 ↗ “Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®” NCT01636076 ↗ “fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate” NCT00975195 ↗ “Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg” NCT02441114 ↗ “Salmeterol xinafoate and Fluticasone propionate HFA pMDI” NCT01795664 ↗ “Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)” NCT02113436 ↗ “Serevent (salmeterol xinafoate inhalation powder)” NCT01361984 ↗ “Drug: Salmeterol xinafoate” NCT02242227 ↗ Show 2 more sources
Known as	Salmetrol Xinafoate	“Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose...” NCT01388595 ↗
Known as	Serevent	“Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose...” NCT01388595 ↗ 5 “Thus, the primary objective for the present study is to compare the two extremes of available long acting beta-agonist formulations - i.e. extra fine HFA formoterol ( Atimos )...” NCT01892787 ↗ “Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers” NCT02254226 ↗ “Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler” NCT01361984 ↗ “Salmeterol 25 µg pMDI HFA (Serevent™)” NCT01344655 ↗ “salmeterol (Serevent, 50 µg b.i.d.)” NCT00239499 ↗
Known as	Serevent Diskus	“A Randomised, Open-label Three-way Crossover Study to Evaluate the Pharmacokinetics of Salmeterol After Inhalation of a 25 μg and 50 μg Single Dose (Inhalation Powder, Hard PE...” NCT02254187 ↗ 3 “Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of...” NCT01110200 ↗ “a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®]” NCT02254174 ↗ “SEREVENT DISKUS® (Salmeterol) Inhlaer” NCT00346749 ↗
Known as	SLM	“Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)” NCT02113436 ↗
Known as	SN408D	“Salmeterol(SN408D)：long-acting Beta2-agonist” NCT00950794 ↗
Action	Activate	“a long-acting beta-agonist” NCT00156819 ↗
Modality	Other / unclassified	“a long-acting beta-agonist” NCT00156819 ↗
Route	Inhaled	“one group will get Salmeterol by multi-dose inhaler (MDI) 2 puffs 2 times a day” NCT00005110 ↗